Medical Marijuana for Tourette’s Syndrome in Ohio

Tourette’s syndrome is one of Ohio’s recognized qualifying conditions for medical marijuana — and one where the research has been accumulating longer than most patients realize. Ohio specifically included Tourette’s syndrome based on research examining THC use in TS patients, as noted in the State Medical Board of Ohio’s covered conditions documentation. For Ohio TS patients whose tics and associated symptoms have not responded adequately to conventional treatments, this page explains what the research actually shows, what realistic expectations look like, and how to approach the evaluation.

Does Tourette’s Syndrome Qualify for Medical Marijuana in Ohio?

Yes. Tourette’s syndrome is explicitly listed as a qualifying condition under Ohio Revised Code Section 3796.01. Ohio law does not restrict this to a specific tic severity level or disease duration. A physician holding a Certificate to Recommend (CTR) issued by the State Medical Board evaluates whether your documented TS diagnosis and symptom picture support a medical marijuana recommendation.

Understanding Tourette’s Syndrome — Tics and Comorbidities

Tourette’s syndrome is a neurodevelopmental disorder characterized by chronic motor and vocal tics — repetitive, involuntary movements and sounds that wax and wane over time. But tics are only part of the Tourette’s picture. A significant majority of TS patients also experience comorbid conditions including obsessive-compulsive disorder, ADHD, anxiety disorders, and depression.

This matters practically for medical marijuana evaluation because the research suggests cannabinoids may affect TS comorbidities differently from tics themselves — and in some cases more consistently. Understanding both dimensions of what medical marijuana may offer is important before pursuing an evaluation.

What Does the Research Show?

The Most Rigorous Study — 2024 Double-Blind Crossover Trial

The most rigorously designed Tourette’s cannabis study to date was a double-blind crossover trial published through PubMed in which 22 participants with severe Tourette’s syndrome were randomly assigned to receive escalating doses of an oral oil containing equal parts THC and CBD or placebo across two 6-week treatment periods.

The primary outcome — total tic score on the Yale Global Tic Severity Scale — showed a reduction of 8.9 points in the active group compared to 2.5 points in the placebo group. The interaction of treatment and visit number on tic score was statistically significant — meaning the active THC:CBD oil produced a meaningfully greater decrease in tics than placebo over the treatment period.

The most common adverse effect in the active treatment period was cognitive difficulties — including slowed thinking, memory lapses, and poor concentration — reported by 8 of 22 participants. This cognitive side effect profile is an important consideration for TS patients who are working or studying.

Earlier Controlled Trials

Two earlier randomized controlled trials — both using oral THC — provide additional controlled evidence. A 6-week double-blind placebo-controlled parallel group study published through PubMed involving 24 TS patients found a significant difference in tic severity scores between the THC and placebo groups — and concluded that THC is effective and safe in the treatment of tics. No serious adverse effects occurred and no neuropsychological impairment was observed.

A retrospective real-world study published through PubMed evaluating cannabis in 19 adult TS patients found tic scores decreased by 60% and 18 of the 19 participants were at least “much improved” — though this was an observational study without a control group.

What a Real-World Medical Cannabis Registry Study Found (H3)

A real-world study published through PubMed examining 70 TS patients using medical cannabis found statistically significant improvements in quality of life, employment status, and reduction in the number of other medications being taken. Among patients with OCD and anxiety comorbidities, 67% and 89% respectively reported improvement.

However — and this is important for Ohio patients to understand — no statistically significant improvement was identified in motor tics, vocal tics, tic frequency, or general mood in this real-world cohort. This finding differs from the controlled trials and highlights that real-world outcomes in heterogeneous patient populations may not match the results of carefully controlled studies.

What the Cochrane Review Concluded

The Cochrane review — representing the highest standard of evidence synthesis — examined the two earliest controlled THC trials involving 28 patients. It concluded that while both trials reported a positive effect from THC, the improvements in tic frequency and severity were small and only detected by some outcome measures. The Cochrane review concluded there was not enough evidence to support the use of cannabinoids in treating tics and OCD in TS — though it acknowledged the limited number and small size of available trials at the time.

The honest overall picture across the research: controlled trials show a statistically significant but modest benefit for tics specifically — with the 2024 trial representing the strongest evidence to date. Quality of life, anxiety comorbidities, and OCD symptoms may respond more consistently than tics themselves in real-world settings.

Cognitive Side Effects — A Specific Consideration for TS Patients

The cognitive side effect finding from the 2024 trial deserves specific attention. Slowed thinking, memory lapses, and poor concentration were the most common adverse effects in the active treatment group. For TS patients who are students, working professionals, or managing ADHD as a comorbidity, these cognitive effects are a meaningful practical consideration that should be discussed with the evaluating physician.

CBD-dominant or lower-THC formulations may be more appropriate starting points for TS patients who are concerned about cognitive side effects — allowing for careful dose adjustment based on individual response.

Tourette’s in Adolescents — An Important Note

Tourette’s syndrome frequently presents in childhood and adolescence. Ohio’s medical marijuana program is available to patients 18 and older — minors require a designated caregiver. A recent open-label pilot study published through PMC became the first to evaluate medicinal cannabis in adolescents with Tourette’s syndrome — finding the protocol feasible and acceptable while noting the need for larger controlled trials in this age group.

For Ohio patients under 18 with Tourette’s syndrome, the evaluation process requires caregiver involvement. A parent or legal guardian serves as the registered caregiver and manages the patient’s medical marijuana use.

What Documentation Do Ohio Tourette’s Patients Need?

Ohio-certified physicians evaluating Tourette’s syndrome patients look for records confirming the diagnosis and capturing the symptom picture. The most important document is records from a neurologist, psychiatrist, or specialist confirming your TS diagnosis — including documentation of tic type, severity, and duration. Treatment history showing medications tried — including alpha-2 agonists, antipsychotics, or behavioral therapy approaches — and their outcomes is helpful. Documentation of comorbid conditions such as OCD, ADHD, or anxiety is relevant if these are part of the symptom burden being addressed. Your current medication list is essential for the OARRS check — particularly relevant if you are taking multiple medications for tics or comorbidities.

Getting Your Ohio Tourette’s Syndrome Evaluation

Ohio’s telemedicine evaluation is completed entirely online — no in-person visit required. After a short intake form, a brief video consultation of 10 to 20 minutes with an Ohio-certified physician covers your TS diagnosis, tic and comorbidity history, current medications, and treatment history. If approved, your recommendation is submitted to the Ohio Patient & Caregiver Registry and your digital card is activated via email — valid at any licensed Ohio dispensary statewide. There is no charge if the physician determines you do not qualify.

If you are an Ohio Tourette’s syndrome patient and want to find out whether you qualify for the medical marijuana program, you can schedule your evaluation here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Covered Conditions — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• THC and CBD in Tourette Syndrome: Double-Blind Crossover Trial — PubMed
• Delta-9-THC Effective in Treatment of Tics: 6-Week Randomized Trial — PubMed
• Preliminary Evidence on Cannabis for Adults With Tourette Syndrome — PubMed
• Medical Cannabis in Tourette’s Syndrome: Real-World Setting — PubMed
• Cannabinoids for Tourette’s Syndrome — Cochrane Review — PubMed
• Medicinal Cannabis for Tics in Adolescents With Tourette Syndrome — PMC / NIH